Psychiatric Medications for Kids: What Parents Need to Ask Before Saying Yes (or No)

When a doctor recommends psychiatric medication for a child, the parent is usually experiencing one of two reactions. One: reflexive fear — medication means something is deeply wrong, it will change who my child is, and we should exhaust every other option first. Two: desperate relief — we have been through years of therapy, everything is getting worse, we need to try something. Both reactions are understandable. Neither is a substitute for actually understanding what the evidence says about the specific medication being recommended, for the specific condition being treated, in children in the specific age range. That information exists. It varies enormously by medication class and by condition. And most parents leave the prescribing appointment without it.

Key Takeaways

• Stimulant medications for ADHD have the longest and most robust evidence base of any psychiatric medication class in children — decades of controlled trials and the most FDA-approved pediatric indications.
• SSRIs for pediatric anxiety and depression have solid evidence but carry an FDA black box warning about suicidal ideation in young people — a real risk that requires specific monitoring, not blanket avoidance.
• Antipsychotics for pediatric mood disorders and irritability have a significantly shorter evidence base in children; their use has expanded substantially while the evidence base lags.
• Medication and therapy are not alternatives to each other. For most pediatric psychiatric conditions, research shows combination treatment outperforms either alone.
• The right questions to ask before agreeing to any pediatric psychiatric medication are specific and concrete — and any good prescriber should be able to answer them.

Stimulants for ADHD: The Evidence Leader

ADHD is the most common neurodevelopmental condition in children, and stimulant medications — methylphenidate (Ritalin, Concerta) and amphetamine compounds (Adderall, Vyvanse) — are the most extensively studied psychiatric medications in pediatric populations.

The evidence is substantial. A 2018 network meta-analysis published in The Lancet Psychiatry examined 81 randomized controlled trials involving over 10,000 children and adolescents with ADHD. The finding: stimulant medications were significantly more effective than placebo for reducing ADHD core symptoms, with methylphenidate performing best in children and amphetamines performing best in adolescents. The effect sizes were moderate to large — not dramatic, but clinically meaningful.

The longitudinal data are also meaningful: a 2021 study following children with ADHD through adulthood found that those who received pharmacological treatment had significantly better outcomes in academic achievement, employment stability, and rates of substance use than those who did not receive medication. This is not a surrogate endpoint — these are real-life outcomes.

What parents often fear but the research doesn’t support:

• “Stimulants will stunt growth” — There is a small documented effect on weight and height velocity in early treatment. Most studies find that children reach their expected height by adulthood. It’s worth monitoring, not a reason to avoid treatment.
• “Stimulants will become a gateway to drug abuse” — The research consistently shows the opposite: treated ADHD reduces risk of substance use disorder. Untreated ADHD is the risk factor.
• “It will change my child’s personality” — Appropriate dosing should reduce symptoms without blunting personality. If a child seems emotionally flat or robotic, that’s a dosing or medication-selection issue to bring to the prescriber.

SSRIs for Anxiety and Depression: Real Evidence, Real Monitoring Requirements

Selective serotonin reuptake inhibitors (SSRIs) — fluoxetine (Prozac), sertraline (Zoloft), escitalopram (Lexapro) — are the most commonly prescribed medications for pediatric anxiety and depression.

The evidence for SSRIs in pediatric anxiety disorders is quite strong. The landmark Child/Adolescent Anxiety Multimodal Study (CAMS), funded by the NIH, compared sertraline, cognitive-behavioral therapy (CBT), their combination, and placebo in children ages 7–17 with anxiety disorders. The combination of sertraline and CBT outperformed all other conditions, with 80.7% of children in the combination group showing significant improvement compared to 59.7% with CBT alone and 54.9% with sertraline alone. Neither therapy nor medication alone was as effective as both together.

For pediatric depression, the evidence is more complicated. Fluoxetine is the only antidepressant with FDA approval for major depressive disorder in children as young as 8. The NIMH-funded Treatment for Adolescents with Depression Study (TADS) found that fluoxetine plus CBT was superior to either treatment alone — again establishing combination treatment as the standard of care.

The Black Box Warning: What It Actually Means

In 2004, the FDA added a black box warning to all antidepressants stating that they increase the risk of suicidal thinking and behavior in children and adolescents. This warning remains in place.

The warning deserves accurate interpretation — not dismissal, and not panic.

The original FDA analysis found a small but statistically significant increase in suicidal ideation (thoughts, not completed suicides) in children taking antidepressants compared to placebo — approximately 4% vs. 2%. No completed suicides occurred in the studies included in the FDA analysis. The effect appears to be greatest in the first few weeks of treatment and in adolescents rather than children.

The clinical implication is specific: children starting an SSRI should be monitored closely in the first 1–4 weeks of treatment, with frequent contact with the prescriber and specific instructions to family members about what to watch for (increased agitation, new or worsening suicidal talk, unusual energy or behavior changes). This monitoring protocol is the appropriate response to the black box warning — not avoiding SSRIs entirely in children who need them.

Antipsychotics: The Evidence Lag

Second-generation antipsychotics (aripiprazole, risperidone, quetiapine, olanzapine) are increasingly prescribed to children for a range of conditions: autism-related irritability, bipolar disorder, treatment-resistant depression, severe ADHD comorbidities. Prescriptions have grown substantially over the past two decades.

The evidence base is significantly thinner than for stimulants or SSRIs. Aripiprazole and risperidone have FDA approval for irritability associated with autism in children ages 5 and older, and this is backed by controlled trial data. The evidence for bipolar disorder in adolescents is reasonable. The evidence for off-label use in young children for conditions like “aggression” or “mood instability” without a specific diagnosis is considerably weaker.

Side effects are real and require monitoring:

• Weight gain and metabolic effects: Many second-generation antipsychotics cause significant weight gain and can affect blood lipids and glucose metabolism. Regular weight and metabolic monitoring is required.
• Extrapyramidal symptoms: Movement-related side effects (restlessness, stiffness, involuntary movements) occur, though less commonly with second-generation than first-generation antipsychotics.
• Tardive dyskinesia: Involuntary movement disorder that can persist after the medication is stopped; risk increases with long-term use.

Pediatric psychiatric organizations, including the American Academy of Child and Adolescent Psychiatry (AACAP), have expressed concern about the rate of antipsychotic prescribing in young children without adequate evidence or monitoring protocols. When an antipsychotic is recommended for a child under 10 without a clear diagnostic indication with FDA support, parents are within their rights to ask for the specific evidence base and to request a second opinion from a pediatric psychiatrist.

Psychiatric Medication Evidence Overview

Medication Class	Common Conditions	Evidence Strength in Children	Key Monitoring
Stimulants (methylphenidate, amphetamines)	ADHD	Very Strong	Blood pressure, weight, height velocity, sleep, appetite
Non-stimulants (atomoxetine, guanfacine)	ADHD (when stimulants problematic)	Moderate–Strong	Blood pressure, mood changes
SSRIs (fluoxetine, sertraline, escitalopram)	Anxiety disorders, depression	Strong for anxiety; Moderate for depression	Suicidal ideation in first 4 weeks; behavior changes
SNRIs (duloxetine, venlafaxine)	Anxiety, depression	Moderate	Similar to SSRIs; GI side effects
Second-generation antipsychotics	Autism irritability, bipolar disorder	Moderate (diagnosis-specific)	Weight, metabolic labs, movement symptoms
Mood stabilizers (lithium, valproate)	Bipolar disorder	Moderate	Blood levels, kidney/liver function
Benzodiazepines	Acute anxiety (short-term)	Limited evidence for long-term	Dependence risk; rarely appropriate for ongoing pediatric use

Questions to Ask Before Agreeing to Medication

Every parent considering psychiatric medication for a child should leave the appointment with clear answers to these questions:

1. What specific diagnosis is this treating? (Medication without a specific diagnosis warrants careful scrutiny.)
2. What is the evidence for this medication in children my child’s age, for this specific condition?
3. What does the FDA approval status look like? (Some pediatric prescriptions are off-label — not necessarily wrong, but worth knowing and discussing.)
4. What is the starting dose, and how will it be titrated?
5. What specific improvements should I expect to see, and in what timeframe?
6. What specific side effects should I watch for and report?
7. What monitoring will happen — how often will we check in, and what will be measured?
8. What happens if this doesn’t work? (There should be a plan B.)
9. Is therapy also part of the plan? (If not, ask why not.)
10. What would prompt us to stop this medication?

A prescriber who cannot or will not answer these questions clearly should prompt a request for a second opinion from a pediatric psychiatrist.

What to Watch For Over 3 Months

Week 1–4: This is the highest-risk period for medication startup, particularly for SSRIs. Watch specifically for: new or increased talk about death or self-harm, significant agitation or restlessness, major mood swings, insomnia worsening, or behavioral changes that seem uncharacteristic. These warrant a call to the prescriber before the scheduled follow-up.

Month 2: If medication is working appropriately, there should be some measurable improvement in the target symptoms — not necessarily complete resolution, but meaningful change. If there’s no improvement at all at 4–6 weeks, that’s a signal for a dose adjustment or reconsideration of diagnosis.

Month 3: Reassess the full picture. Is therapy also happening? The research consistently shows that combination treatment (medication plus evidence-based therapy) outperforms medication alone for most pediatric psychiatric conditions. If medication has been started without a therapy component, this is the time to add one.

Frequently Asked Questions

How do I know if my child actually needs medication and not just therapy?

For most pediatric mental health conditions, therapy — particularly cognitive-behavioral therapy — should be tried first unless the symptoms are severe, impairing, and acutely interfering with the child’s functioning. The CAMS and TADS studies suggest that combination treatment (therapy plus medication) typically outperforms either alone. A good prescriber will discuss the role of therapy alongside any medication recommendation, not instead of the conversation about therapy.

My child’s primary care doctor prescribed an SSRI. Should I get a second opinion?

Primary care physicians do prescribe SSRIs for pediatric anxiety and depression, and this is appropriate — they have training in this area. However, for complex presentations, multiple diagnoses, young children (under 6), or medication that isn’t working as expected, a referral to a child and adolescent psychiatrist is reasonable and worth requesting. Psychiatrists have more specialized training in pediatric psychopharmacology.

What happens if we stop medication abruptly?

This depends heavily on the medication class. Stimulants can generally be stopped without physical dependence concerns, though ADHD symptoms will return. SSRIs should typically be tapered rather than stopped abruptly — discontinuation syndrome (flu-like symptoms, dizziness, irritability) can occur with abrupt cessation. Antipsychotics should always be tapered under physician supervision. Never stop a psychiatric medication without discussing the discontinuation plan with the prescriber.

Are psychiatric medications addictive?

Stimulants (Schedule II controlled substances) have abuse potential, but this risk is significantly lower when used as prescribed for a genuine ADHD diagnosis than when misused recreationally. SSRIs and antipsychotics are not addictive in the traditional pharmacological sense, though SSRIs can produce discontinuation symptoms if stopped abruptly. The question worth asking is not “could this cause addiction?” but “what is the specific risk profile for this medication in my child, given their history and diagnosis?”

---

About the author

Ricky Flores is the founder of HiWave Makers and an electrical engineer with 15+ years of experience building consumer technology at Apple, Samsung, and Texas Instruments. He writes about how kids learn to build, think, and create in a tech-saturated world. Read more at hiwavemakers.com.

---

Sources

1. Cortese, S., Adamo, N., Del Giovane, C., et al. (2018). “Comparative Efficacy and Tolerability of Medications for ADHD in Children, Adolescents, and Adults.” The Lancet Psychiatry, 5(9), pp. 727–738. https://doi.org/10.1016/S2215-0366(18)30269-4
2. Walkup, J.T., Albano, A.M., Piacentini, J., et al. (2008). “Cognitive Behavioral Therapy, Sertraline, or a Combination in Childhood Anxiety.” New England Journal of Medicine, 359(26), pp. 2753–2766. https://doi.org/10.1056/NEJMoa0804633
3. March, J., Silva, S., Petrycki, S., et al. (2004). “Fluoxetine, Cognitive-Behavioral Therapy, and Their Combination for Adolescents with Depression.” JAMA, 292(7), pp. 807–820. https://doi.org/10.1001/jama.292.7.807
4. U.S. Food and Drug Administration. (2004). “FDA Public Health Advisory: Suicidality in Children and Adolescents Being Treated With Antidepressant Medications.” https://www.fda.gov/
5. American Academy of Child and Adolescent Psychiatry. (2020). “Practice Parameters for the Use of Psychotropic Medication in Children and Adolescents.” https://www.aacap.org/
6. Fombonne, E. (2020). “Trends in Autism Spectrum Disorder Prevalence.” JAMA, 324(9), p. 848. https://doi.org/10.1001/jama.2020.4999
7. Lichtenstein, P., Halldner, L., Zetterqvist, J., et al. (2012). “Medication for Attention Deficit–Hyperactivity Disorder and Criminality.” New England Journal of Medicine, 367(21), pp. 2006–2014.